Understanding the relationship between norovirus diversity and immunity

被引:38
作者
A. Ford-Siltz, Lauren [1 ]
Tohma, Kentaro [1 ]
I. Parra, Gabriel [1 ]
机构
[1] US FDA, Div Viral Prod, Ctr Biol Evaluat & Res, 10903 New Hampshire Ave,Bldg 52-72,Room 1308, Silver Spring, MD 20993 USA
关键词
Norovirus; gastroenteritis; immunity; vaccines; correlates of protection; VIRUS-LIKE PARTICLES; BLOOD GROUP ANTIGENS; GENOGROUP-II; NEUTRALIZING ANTIBODY; MONOCLONAL-ANTIBODY; STRUCTURAL BASIS; SECRETOR FUT2; BIRTH COHORT; VP6; PROTEIN; GII.4;
D O I
10.1080/19490976.2021.1900994
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Human noroviruses are the most common viral cause of acute gastroenteritis worldwide. Currently, there are no approved vaccines or specific therapeutics to treat the disease. Some obstacles delaying the development of a norovirus vaccine are: (i) the extreme diversity presented by noroviruses; (ii) our incomplete understanding of immunity to noroviruses; and (iii) the lack of a robust cell culture system or animal model for human noroviruses. Recent advances in in vitro cultivation of norovirus, novel approaches applied to viral genomics and immunity, and completion of vaccine trials and birth cohort studies have provided new information toward a better understanding of norovirus immunity. Here, we will discuss the complex relationship between norovirus diversity and correlates of protection for human noroviruses, and how this information could be used to guide the development of cross-protective vaccines.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 104 条
[1]   Antibody Responses to Norovirus Genogroup GI.1 and GII.4 Proteases in Volunteers Administered Norwalk Virus [J].
Ajami, Nadim J. ;
Barry, Meagan A. ;
Carrillo, Berenice ;
Muhaxhiri, Zana ;
Neill, Frederick H. ;
Prasad, B. V. Venkataram ;
Opekun, Antone R. ;
Gilger, Mark A. ;
Graham, David Y. ;
Atmar, Robert L. ;
Estes, Mary K. .
CLINICAL AND VACCINE IMMUNOLOGY, 2012, 19 (12) :1980-1983
[2]   Human Monoclonal Antibodies That Neutralize Pandemic GII.4 Noroviruses [J].
Alvarado, Gabriela ;
Ettayebi, Khalil ;
Atmar, Robert L. ;
Bombardi, Robin G. ;
Kose, Nurgun ;
Estes, Mary K. ;
Crowe, James E., Jr. .
GASTROENTEROLOGY, 2018, 155 (06) :1898-1907
[3]   Understanding and Manipulating Viral Immunity: Antibody Immunodominance Enters Center Stage [J].
Angeletti, Davide ;
Yewdell, Jonathan W. .
TRENDS IN IMMUNOLOGY, 2018, 39 (07) :549-561
[4]  
[Anonymous], 2019, VAXARTS TABLETED ORA
[5]   Norovirus GII. P16/GII.2-Associated Gastroenteritis, China, 2016 [J].
Ao, Yuanyun ;
Wang, Jinjin ;
Ling, Hua ;
He, Yaqing ;
Dong, Xiaogeng ;
Wang, Xuan ;
Peng, Jingyao ;
Zhang, Hailong ;
Jin, Miao ;
Duan, Zhaojun .
EMERGING INFECTIOUS DISEASES, 2017, 23 (07) :1172-1175
[6]   Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice [J].
Arunkumar, Guha Asthagiri ;
Ioannou, Andriani ;
Wohlbold, Teddy John ;
Meade, Philip ;
Aslam, Sadaf ;
Amanat, Fatima ;
Ayllon, Juan ;
Garcia-Sastre, Adolfo ;
Krammer, Florian .
JOURNAL OF VIROLOGY, 2019, 93 (06)
[7]   Norwalk virus shedding after experimental human infection [J].
Atmar, Robert L. ;
Opekun, Antone R. ;
Gilger, Mark A. ;
Estes, Mary K. ;
Crawford, Sue E. ;
Neill, Frederick H. ;
Graham, David Y. .
EMERGING INFECTIOUS DISEASES, 2008, 14 (10) :1553-1557
[8]   Comparison of Microneutralization and Histo-Blood Group Antigen-Blocking Assays for Functional Norovirus Antibody Detection [J].
Atmar, Robert L. ;
Ettayebi, Khalil ;
Ayyar, B. Vijayalakshmi ;
Neill, Frederick H. ;
Braun, Ralph P. ;
Ramani, Sasirekha ;
Estes, Mary K. .
JOURNAL OF INFECTIOUS DISEASES, 2020, 221 (05) :739-743
[9]   An Exploratory Study of the Salivary Immunoglobulin A Responses to 1 Dose of a Norovirus Virus-Like Particle Candidate Vaccine in Healthy Adults [J].
Atmar, Robert L. ;
Cramer, Jakob P. ;
Baehner, Frank ;
Han, Cong ;
Borkowski, Astrid ;
Mendelman, Paul M. .
JOURNAL OF INFECTIOUS DISEASES, 2019, 219 (03) :410-414
[10]  
Atmar RL, 2018, CURR OPIN INFECT DIS, V31, P422, DOI [10.1097/QCO.0000000000000476, 10.1097/qco.0000000000000476]